Favipiravir, wanda ake sayar da shi a ƙarƙashin sunan alamar Avigan da sauransu, maganin rigakafi ne wanda ake amfani da shi don magance mura a Japan. Hakanan ana nazarinta don kula da adadin wasu cututtukan ƙwayoyin cuta, gami da SARS-CoV-2. Kamar magungunan rigakafin gwaji na T-1105 da T-1106, abin da aka samu na pyrazinecarboxamide ne. Toyama Chemical (wani reshen Fujifilm ) ne ke haɓakawa da ƙera shi kuma an amince da shi don amfanin likita a Japan a cikin 2014. A cikin 2016, Fujifilm ya ba shi lasisi ga Zhejiang Hisun Pharmaceutical Co. na China. Ya zama magani gama-gari a shekarar 2019, wanda ya baiwa kamfanin damar samar da shi a cikin Jamhuriyar Jama'ar Sin.[ana buƙatar hujja] An amince da Favipiravir don maganin mura a Japan. An yi, duk da haka, kawai an nuna shi ga sabon mura (cututtukan da ke haifar da cututtuka masu tsanani) maimakon mura na yanayi Tun daga 2020, yuwuwar juriya ta haɓaka tana bayyana ƙasa kaɗan. Akwai shaida cewa yin amfani da lokacin daukar ciki na iya haifar da lahani ga jariri.